BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TVAX-028 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TVAX-028\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07673068-10228@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:TVAX-028: Phase 1 readout est. (NCT07673068)
DESCRIPTION:TVAX-028\, phase 1\, Chronic Hepatitis B.\nStudy: Clinical Tria
 l to Evaluate the Safety\, Tolerability\, and Pharmacokinetic Profile of T
 VAX-028 in the Treatment of Chronic Hepatitis B\nEstimated primary complet
 ion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tva
 x-028#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07673068
URL:https://assetmemo.bio/drug/tvax-028#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
